The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
 
Ilya Tsimafeyeu
Leadership - Ruspharmtech
Stock and Other Ownership Interests - Ilgen; Ruspharmtech
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Ruspharmtech
Research Funding - Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Kidney Cancer Research Bureau; Oncomax LLC; Ruspharmtech
 
Pavel Borisov
No Relationships to Disclose
 
Ahmed Abdelgafur
No Relationships to Disclose
 
Roman Leonenkov
No Relationships to Disclose
 
Olga Novikova
No Relationships to Disclose
 
Irina Guseva
No Relationships to Disclose
 
Marina Demchenkova
No Relationships to Disclose
 
Nadezhda Mikhailova
No Relationships to Disclose
 
Andrey Semenov
No Relationships to Disclose
 
Zakhar Yurmazov
No Relationships to Disclose
 
Irina Sivunova
No Relationships to Disclose
 
Madina Ramazanova
No Relationships to Disclose
 
Sergey Gamayunov
No Relationships to Disclose
 
Dmitry Kosov
No Relationships to Disclose